Tag: checkpoint blocker
Innovative cancer therapies can provide a new hope
AstraZeneca is testing a checkpoint blocker in a late-stage clinical trial as a treatment for non-small-cell lung cancer. The drug causes both parts of the immune response because it blocks an inhibitoryreceptor found on NK cell and some T cells, researchers said. In a study of 37 people with blood cancer, researchers found that those who received their cells from a cord-blood unit survived over 70%.
Read More